Imugene (ASX: IMU) is expected to trade higher following the company being allowed a European patent for its Linguet™ drug delivery technology.
It is significant as it protects around Linguet’s™ formulations and other specific excipients for a class of drugs that prevent the loss of bone mass.
The European Patent Office has issued an Intention to Grant Communication for Linguet™.
Linguet is now protected by the same patent in three key markets including Europe, Japan and China.
The patent is another step for Imugene on the path to commercialisation adding value to its core technology.
The next key milestone to be achieved for the company is the U.S. patent application, which would effectively provide Imugene with global coverage.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.